Related Experiment Video
Updated: Mar 13, 2026
Author Spotlight: Advancing Liver Regeneration Research through ALPPS Mouse Model
Published on: January 19, 2024
Graft and Patient Survival After Liver Transplantation for Primary Sclerosing Cholangitis: A French National Cohort
Florian Veyre1,2, Claire Francoz3, Domitille Erard1
1Service D'hépato-Gastroentérologie, Centre de Référence Des Maladies Inflammatoires Des Voies Biliaires et Des hépatites Autoimmunes-Filière FILFOIE, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.
Background:
A significant proportion of patients presenting a primary sclerosing cholangitis (PSC) will require liver transplantation (LT). The present study aimed to investigate graft loss and patient death in a large cohort of patients.
Methods:
We conducted a nationwide multicenter retrospective study including all adult patients transplanted for PSC in France From 1985 to 2019.
Results:
Were included 571 patients; median follow-up after LT was 89.0 months (IQR, 43.0-151.0). Patient survival at 5, 10 and 20 years after LT was 88.2%, 81.2% and 62.6%. After exclusion of patients who died during the first month after LT, 37 patients (6.6%) died during the first 2 years and the main cause was malignancies (n = 15, 40.5%, including 12 cases of recurrent cholangiocellular carcinoma). After 2 years, 90 patients (17.2%) died; the two main causes were malignancies (n = 36, 40.0%, including 13 cases of colorectal cancer) and sepsis (n = 23, 25.6%, of which 7 were related to recurrent PSC). Graft survival at 5, 10 and 20 years was 89.5%,78.7% and 62.7%. Independent factors associated with late patient death (after 2 years) were an older age at LT, a bilio-digestive anastomosis and the use of preventive UDCA; independent factors associated with late graft loss were recurrent PSC, cellular rejection, a younger age at LT, and the use of tacrolimus (protective).
Conclusions:
Our results emphasise that the prognosis after LT for PSC could be improved by better detection of cholangiocellular carcinoma before LT, and colorectal cancer after LT.
